The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
French immunotherapeutics-focussed biotech firm Transgene has appointed Steven Bloom as vice president, chief business officer with immediate effect. 10 February 2022
Following consultation with members – and heeding the concerns of the Consumers Health Forum (CHF) and patient groups – pharma trade group Medicines Australia reiterates its call to have finalization of the new National Medicines Policy (NMP) delayed until after the federal election. 10 February 2022
The US Food and Drug Administration said yesterday that it has taken new steps aimed at fostering the development of non-addictive alternatives to opioids to manage acute pain and decreasing exposure to opioids and preventing new addiction. 10 February 2022
The US regulator has accepted for Priority Review a bid to broaden the label for the antibody Dupixent (dupilumab) in moderate-to-severe atopic dermatitis. 10 February 2022
Shares of Danish CNS specialist Lundbeck closed down 7.4% at 148.55 kroner after it reported financial results for the fourth quarter and full year 2021. 10 February 2022
GlobalData has identified that drug pricing pressures are seen as the major hindrance to the growth of the pharmaceutical industry in 2022, forcing companies to reassess their pricing strategies and market focus. 10 February 2022
German infectious disease drug developer AiCuris and Netherlands-based biotech Hybridize Therapeutics today announced that they have entered into a worldwide licensing agreement for Hybridize’s BK virus (BKV) program. 9 February 2022
US biotech firm Ventus Therapeutics, which is developing small molecule therapeutics across a broad range of disease indications, announced today the closing of a $140 million Series C financing. 9 February 2022
UK-headquartered pharma services and products company Clinigen Group announced it has signed a distribution agreement, with USA-based Deciphera Pharmaceuticals for the supply and distribution of Qinlock (ripretinib) into multiple countries across the globe. 9 February 2022
Presenting an upbeat set of financial results, the company’s first since refusing a £50 billion ($68.4 billion) offer for its consumer health unit, GlaxoSmithKline said it took in £34.1 billion in 2021, £9.5 billion of which came in the final quarter. 9 February 2022
Indian drugmaker Lupin Limited today announced that it has entered into a distribution agreement with Slovenia-based Medis Pharmaceutical for Lupin’s orphan drug NaMuscla (mexiletine). 9 February 2022
German biopharmaceutical contract development and manufacturing organization (CDMO AGC Biologics has expanded its partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, Comirnaty, at the company’s Heidelberg facility. 9 February 2022
French biotech MaaT Pharma has entered into a partnership agreement with contract development and manufacturing organization (CDMO) Skyepharma to build what to date will be France’s largest specialized cGMP manufacturing facility for ecosystem microbiome-based therapeutics. 9 February 2022
Since the early days of the pandemic, a number of developers have pursued the concept of using a nasal spray to administer anti-virals for treatment and prevention of coronavirus. 9 February 2022
US neurological diseases specialist Ovid Therapeutics and AI-powered drug discovery company Healx have announced a strategic partnership. 8 February 2022
US cancer-focussed firm Karyopharm Therapeutics saw its shares plunge nearly 23% to $7.93 by mid-morning, despite the company releasing a bullish statement on a new trial of its already marketed drug Nexpovio/Xpovio (selinexor) as a treatment for endometrial cancer. 8 February 2022
New Jersey-based Outlook Therapeutics, a biopharma company working to develop and launch the first approved ophthalmic formulation of bevacizumab for use in retinal indications, has announced the appointment of Joel Prieve as senior vice president, Commercial Operations. 8 February 2022
US biotech giant Amgen late yesterday announced financial results for the fourth quarter and full year 2021, with earnings coming in ahead of analysts’ forecasts. 8 February 2022
US pharma giant Pfizer’s chairman and chief executive Albert Bourla was able to bask in the glory of a record-breaking year when he presented the group’s fourth-quarter and annual financial results for 2021 on Tuesday. 8 February 2022